about
Evaluation of body mass index, pre-vaccination serum progesterone levels and anti-anthrax protective antigen immunoglobulin G on injection site adverse events following anthrax vaccination in womenThe Vaccine Safety Datalink: successes and challenges monitoring vaccine safety.A cluster of nonspecific adverse events in a military reserve unit following pandemic influenza A (H1N1) 2009 vaccination-possible stimulated reporting?Assessment of anthrax vaccination data in the Defense Medical Surveillance System, 1998-2004.Quality assessment of nonanthrax vaccination data in the Defense Medical Surveillance System (DMSS), 1998-2004.Integration of data from a safety net health care system into the Vaccine Safety Datalink.Vaccine adverse events in a safety net healthcare system and a managed care organization.Adverse events following quadrivalent meningococcal CRM-conjugate vaccine (Menveo®) reported to the Vaccine Adverse Event Reporting system (VAERS), 2010-2015.Mycobacterium septicum sp. nov., a new rapidly growing species associated with catheter-related bacteraemia.An epidemic of Malassezia pachydermatis in an intensive care nursery associated with colonization of health care workers' pet dogs.Short-term reactogenicity and gender effect of anthrax vaccine: analysis of a 1967-1972 study and review of the 1955-2005 medical literature.Molecular epidemiologic evaluation of endocarditis due to Oerskovia turbata and CDC group A-3 associated with contaminated homograft valves.Adverse Events Following Measles, Mumps, and Rubella Vaccine in Adults Reported to the Vaccine Adverse Event Reporting System (VAERS), 2003-2013Infections due to Nocardia transvalensis: clinical spectrum and antimicrobial therapy.Development of the Vaccine Analytic Unit's research agenda for investigating potential adverse events associated with anthrax vaccine adsorbed.Risk of anaphylaxis after vaccination in children and adultsAbscesses due to mycobacterium abscessus linked to injection of unapproved alternative medication.The Centers for Disease Control and Prevention's public health response to monitoring Tdap safety in pregnant women in the United StatesVaccination and risk of type 1 diabetes mellitus in active component U.S. Military, 2002-2008.Post-licensure surveillance of trivalent live attenuated influenza vaccine in adults, United States, Vaccine Adverse Event Reporting System (VAERS), July 2005-June 2013.Concurrent vaccinations and U.S. military hospitalizations.Assessing misclassification of vaccination status: Implications for studies of the safety of the childhood immunization schedule.Anthrax Vaccine and the Risk of Rheumatoid Arthritis and Systemic Lupus Erythematosus in the U.S. Military: A Case-Control Study.Association of Tdap Vaccination With Acute Events and Adverse Birth Outcomes Among Pregnant Women With Prior Tetanus-Containing Immunizations.Improving Human Papillomavirus Vaccine Use in an Integrated Health System: Impact of a Provider and Staff Intervention.Risk of non-targeted infectious disease hospitalizations among U.S. children following inactivated and live vaccines, 2005-2014.Vaccination and 30-Day Mortality Risk in Children, Adolescents, and Young Adults.Acremonium kiliense endophthalmitis that occurred after cataract extraction in an ambulatory surgical center and was traced to an environmental reservoir.Association between parent attitudes and receipt of human papillomavirus vaccine in adolescents.Post licensure surveillance of influenza vaccines in the Vaccine Safety Datalink in the 2013-2014 and 2014-2015 seasons.Continuous sequential boundaries for vaccine safety surveillance.Who is unlikely to report adverse events after vaccinations to the Vaccine Adverse Event Reporting System (VAERS)?Current safety issues with quadrivalent meningococcal conjugate vaccines.Risk of fatal adverse events after H1N1 influenza vaccine: limitations of passive surveillance data.Phenotypic and molecular epidemiologic evaluation of a Nocardia farcinica mastitis epizootic.Health-related quality of life in the Anthrax Vaccination Program for workers in the Laboratory Response Network.Military healthcare providers reporting of adverse events following immunizations to the vaccine adverse event reporting system.Anthrax vaccination and risk of optic neuritis in the United States military, 1998-2003.Serious adverse events among participants in the Centers for Disease Control and Prevention's Anthrax Vaccine and Antimicrobial Availability Program for persons at risk for bioterrorism-related inhalational anthrax.Trends in prescribing for vulvovaginal candidiasis in the United States.
P50
Q23924129-6615E791-F1FC-45F6-A419-8E0D6BD5A037Q30365533-98DDED74-90AF-4126-AC8E-B623E98690F8Q30412637-43DC188E-4DA7-40BF-8B77-0374EB544EC3Q31109539-F972D9E9-BC79-4C44-8AE6-0346E5AC6ABBQ31147547-470875BC-F3CE-47D5-A840-7202ED2E0B1DQ31159604-C3458E84-C3B0-44CE-AD02-71D4C628B69EQ33168249-BF9714EF-1DF8-4D7B-AD32-51354547D14BQ33168344-92562D21-3674-49EE-A80E-B6FBABF6672DQ33180130-1502A5BC-B422-4EA8-97DB-5303BBD6B1A7Q34459454-04A51DB4-62EC-46C2-981A-19F1F4B3E1FFQ34605455-297C1264-E647-4256-AF53-50DB8EDB18ADQ34780055-8C3059DB-35B4-4366-A8EA-15CC98C2C941Q35661817-15E397C6-2236-41FA-9F0E-B96021B4E1C9Q35811322-D297EAF9-3748-4A8F-90FA-32257D1223E8Q36380946-3AB6D3D2-8654-44C8-B02F-15BF36BAF0A6Q36665226-1A48C7BD-F92B-49A5-9451-B8A2F4C5D0FAQ37064426-B6944631-8E6C-4AD0-96A5-A1E2604BF608Q37320137-776334D9-10FE-409D-829F-44FDB173C4DFQ37954854-6CF0E3E1-018D-428C-AFE8-B40494C5CDE4Q38254540-BFFE6468-1BCE-4ECA-BA80-26290C312F46Q38462070-BF0AA6F7-080B-41CE-B898-0816FAB55F10Q38912502-2087F2C2-F7C6-416B-B918-CF123A45FAE8Q38983818-D58CBF42-F6CD-44ED-886C-B81FE6EA5BF5Q40133941-8A0022DB-2434-4490-8AEA-905FFFE8603DQ40219237-CBD7C57F-4110-4502-A3A6-66CC146A0647Q40221930-4E522DA0-BAE0-4E90-9B41-E8052C7C36E9Q40891787-9717CD15-02C7-4BD2-8E8D-9CDE43AF9D8BQ41136619-92CB9A0E-EFE4-4E43-9593-BFD28942480CQ42051867-14ACE35A-9491-4F09-811D-71796C3A4941Q42081471-E40960E8-9E14-4851-88C1-3025E4E8681BQ42221013-5A1ED089-F071-4A5C-B1A6-D99DAB47F7BDQ42266126-A9F85F61-6960-4F89-A075-88EF926A3FC6Q43168629-CBC284BC-9C8F-411E-ADA8-33046F53435DQ43173714-6A168636-4AA9-4B17-98A9-487FA23C352CQ43222674-AEA9970A-10B6-4416-A3FE-8F53B95D05BFQ43230753-CA853B69-0E38-4BA3-B61C-48A79FC356E9Q43458355-C55CF6CC-5651-4221-8C3C-9791ECC43FDEQ44170010-11C580AD-02FA-4632-96D7-A438EE026B5DQ44586740-1554D5E1-8C80-4F97-B314-3DD31CBD9FB1Q45073888-C7B5BE6C-EEC9-4258-8AE4-8F30B56C70B5
P50
description
researcher ORCID ID = 0000-0003-0713-8312
@en
name
Michael M McNeil
@ast
Michael M McNeil
@en
Michael M McNeil
@es
Michael M McNeil
@nl
type
label
Michael M McNeil
@ast
Michael M McNeil
@en
Michael M McNeil
@es
Michael M McNeil
@nl
prefLabel
Michael M McNeil
@ast
Michael M McNeil
@en
Michael M McNeil
@es
Michael M McNeil
@nl
P31
P496
0000-0003-0713-8312